DOI QR코드

DOI QR Code

An anti-viral peptide derived from the preS1 surface protein of hepatitis B virus

  • Kim, Do-Hyoung (Molecular Cancer Research Center, Division of Molecular Therapeutics, Korea Research Institute of Bioscience and Biotechnology) ;
  • Ni, Yi (University of Heidelberg, Department of Molecular Virology, Otto-Meyerhof-Zentrum (OMZ)) ;
  • Lee, Si-Hyung (Molecular Cancer Research Center, Division of Molecular Therapeutics, Korea Research Institute of Bioscience and Biotechnology) ;
  • Urban, Stephan (University of Heidelberg, Department of Molecular Virology, Otto-Meyerhof-Zentrum (OMZ)) ;
  • Han, Kyou-Hoon (Molecular Cancer Research Center, Division of Molecular Therapeutics, Korea Research Institute of Bioscience and Biotechnology)
  • Published : 2008.09.30

Abstract

The preS1 surface protein of the hepatitis B virus (HBV) is a key factor involved in initial viral entry into hepatocytes. It has been long postulated that an anti-HBV effect should be achievable using peptide fragments of the preS1. Recent reports demonstrated that several preS1-derived lipo-peptides in genotype D HBV exhibit nano to picomolar inhibitory activity against HBV infection. In this study, an acylated analog of a preS1 fragment, a 21-residue lipo-peptide (named 7524 BVS7) with a sequence of palmitoyl-GMGTNLSVPNPLGFFPDHQLDC-$NH_2$, from genotype C HBV was produced base upon a previous structural study and was shown potently inhibits HBV infection with an $IC_{50}$ of $\approx$ 20 nM.

Keywords

References

  1. Fung, S. K. and Lok, A. S. (2004) Viral hepatitis in 2003. Curr. Opin. Gastroenterol. 20, 241-247 https://doi.org/10.1097/00001574-200405000-00008
  2. Rehermann, B. and Nascimbeni, M. (2005) Immunology of hepatitis B virus and hepatitis C viruss infection. Nat. Rev. Immunol. 5, 215-229 https://doi.org/10.1038/nri1573
  3. Wright, T. L. (2006) Introduction to chronic hepatitis B infection. Am. J. Gastroenterol. 101, Suppl 1: S1-6 https://doi.org/10.1111/j.1572-0241.2006.00460.x
  4. Blumberg, B. S., Millman, I., Venkateswaran, P. S. and Thyagarajan, S. P. (1989) Hepatitis B virus and hepatocellular carcinoma--treatment of HBV carriers with Phyllanthus amarus. Cancer. Detect. Prev. 14, 195-201
  5. Stephenne, J. (1990) Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. Vaccine 8, Suppl: S69-73; discussion S79-80 https://doi.org/10.1016/0264-410X(90)90224-A
  6. Mahoney, F. J., Woodruff, B. A., Erben, J. J., Coleman, P. J., Reid, E. C., Schatz, G. C. and Kane, M. A. (1993) Effect of a hepatitis B vaccination program on the prevalence of hepatitis B virus infection. J. Infect. Dis. 167, 203-207 https://doi.org/10.1093/infdis/167.1.203
  7. Jilg, W. (1998) Novel hepatitis B vaccines. Vaccine 16, Suppl: S65-68 https://doi.org/10.1016/S0264-410X(98)00300-4
  8. Burton, D. R., Desrosiers, R. C., Doms, R. W., Koff, W. C., Kwong, P. D., Moore, J. P. Nabel, G. J., Sodroski, J., Wilson, I. A. and Wyatt, R. T. (2004) HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5, 233-236 https://doi.org/10.1038/ni0304-233
  9. Zoulim, F. (2006) Antiviral therapy of chronic hepatitis B. Antiviral Res. 71, 206-215 https://doi.org/10.1016/j.antiviral.2006.04.003
  10. Shin, D., Kim, S. I., Kim, M. and Park, M. (2006) Efficient inhibition of hepatitis B virus replication by small interfering RNAs targeted to the viral X gene in mice. Virus. Res. 119, 146-153 https://doi.org/10.1016/j.virusres.2005.12.012
  11. Saag, M. S. (2006) Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus. Clin. Infect. Dis. 42, 126-131 https://doi.org/10.1086/498348
  12. Root, M. J. and Steger, H. K. (2004) HIV-1 gp41 as a target for viral entry inhibition. Curr. Pharm. Des. 10, 1805-1825 https://doi.org/10.2174/1381612043384448
  13. De Clercq, E. (2006) Antiviral agents active against influenza A viruses. Nature Rev. Drug Disc. 5, 1015-1025 https://doi.org/10.1038/nrd2175
  14. Petersen, J., Dandri, M., Mier, W., Lutgehetmann, M., Volz, T., von Weizsacker, F., Haberkorn, U., Fischer, L., Pollok, J-M., Erbes, B, Seitz, S. and Urban, S. (2007) Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat. Biotech. 26, 335-341 https://doi.org/10.1038/nbt1389
  15. Gripon, P., Le, S. J., Rumin, S. and Guguen-Guillouzo, C. (1995) Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity. Virology. 213, 292-299 https://doi.org/10.1006/viro.1995.0002
  16. LeSeyec, J., Chouteau, P., Cannie, I., Guguen-Guillouzo, C. and Gripon, P. (1999) Infection process of the hepatitis B virus depends on the presence of a defined sequence in the pre-S1 domain. J. Virol. 73, 2052-2057
  17. Barrera, A., Guerra, B., Notvall, L. and Lanford, R. E. (2005) Mapping of the hepatitis B virus pre-S1 domain involved in receptor recognition. J. Virol. 79, 9786-9798 https://doi.org/10.1128/JVI.79.15.9786-9798.2005
  18. Glebe, D., Urban, S., Knoop, E.V., Cag, N., Krass, P., Grun, S., Bulavaite, A., Sasnauskas, K. and Gerlich, W.H. (2005) Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology 129, 234-245 https://doi.org/10.1053/j.gastro.2005.03.090
  19. Engelke, M., Mills, K., Seitz, S., Simon, P., Gripon, P., Schnolzer, M. and Urban, S. (2006) Characterization of a hepatitis B and hepatitis delta virus receptor binding site. Hepatology 43, 750-760 https://doi.org/10.1002/hep.21112
  20. Neurath, A. R., Kent, S. B., Strick, N. and Parker, K. (1986) Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 46, 429-436 https://doi.org/10.1007/s12275-007-0163-y
  21. Chan, D. C. and Kim, P. S. (1998) HIV entry and its inhibition. Cell 93, 681-684 https://doi.org/10.1016/S0092-8674(00)81430-0
  22. Heermann, K. H., Goldmann, U., Schwartz, W., Seyffarth, T., Baumgarten, H. and Gerlich, W. H. (1984) Large surface proteins of hepatitis B virus containing the pre-s sequence. J. Virol. 52, 396-402
  23. Maeng, C. Y., Oh, M. S., Park, I. H. and Hong, H. J. (2001) Purification and structural analysis of the hepatitis B virus preS1 expressed from Escherichia coli. Biochem. Biophys. Res. Commun. 282, 787-792 https://doi.org/10.1006/bbrc.2001.4641
  24. Chi, S. W., Kim, D. H., Lee, S. H., Chang, I. and Han, K. (2007) Pre-structured motifs in the natively unstructured preS1 surface antigen of hepatitis B virus. Prot. Sci. 16, 2108-2117 https://doi.org/10.1110/ps.072983507
  25. Lee, H., Mok, K. H., Muhandiram, R., Park, K. H., Suk, J. E., Kim, D. H., Chang, J., Sung, Y. C., Choi, K. Y. and Han, K. H. (2000) Local structural elements in the mostly unstructured transcriptional activation domain of human p53. J. Biol. Chem. 275, 29426-29432 https://doi.org/10.1074/jbc.M003107200
  26. Chi, S. W., Lee, S. H., Kim, D. H., Ahn, M. J., Kim, J. S., Woo, J. Y., Torizawa, T., Kainosho, M. and Han, K. H. (2005) Structural details on mdm2-p53 interaction. J. Biol. Chem. 280, 38795-38802 https://doi.org/10.1074/jbc.M508578200
  27. Ramelot, T. A., Gentile, L. N. and Nicholson, L. K. (2000) Transient structure of the amyloid precursor protein cytoplasmic tail indicates preordering of structure for binding to cytosolic factors. Biochemistry 39, 2714-2725 https://doi.org/10.1021/bi992580m
  28. Sayers, E. W., Gerstner, R. B., Draper, D. E. and Torchia, D. A. (2000) Structural preordering in the N-terminal region of ribosomal protein S4 revealed by heteronuclear NMR spectroscopy. Biochemistry 39, 13602-13613 https://doi.org/10.1021/bi0013391
  29. Bienkiewicz, E. A., Adkins, J. N. and Lumb, K. J. (2002) Functional consequences of preorganized helical structure in the intrinsically disordered cell-cycle inhibitor p27(Kip1). Biochemistry 41, 752-759 https://doi.org/10.1021/bi015763t
  30. Bochkareva, E., Kaustov, L., Ayed, A., Yi, G. S., Lu, Y., Pineda-Lucena, A., Liao, J. C., Okorokov, A. L., Milner, J., Arrowsmith, C. H. and Bochkarev, A. (2005) Singlestranded DNA mimicry in the p53 transactivation domain interaction with replication protein A. Proc. Natl. Acad. Sci. 102, 15412-15417 https://doi.org/10.1073/pnas.0504614102
  31. Di Lello, P., Jenkins, L. M., Jones, T. N., Nguyen, B. D., Hara, T., Yamaguchi, H., Dikeakos, J. D., Appella, E., Legault, P. and Omichinski, J.G. (2006) Structure of the Tfb1/p53 complex: Insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. Mol. Cell. 22, 731-740
  32. Neurath, A.R., Adamowicz, P., Riottot, M.M., Prince, P., Strick, N., Parker, K., Petit, M. A., Budkowska, A. and Girard, M. (1987) Immunological cross-reactivity between preS2 sequences of the hepatitis B virus envelope proteins corresponding to serological subtypes adw2 and ayw. Mol. Immunol. 24, 561-568 https://doi.org/10.1016/0161-5890(87)90036-8
  33. Gripon, P., Rumin, S., Urban, S., Le Seyec, J., Glaise, D., Cannie, I., Guyomard, C., Lucas, J., Trepo, C. and Guguen- Guillouzo, C. (2002) Infection of a human hepatoma cell line by hepatitis B virus. Proc. Natl. Acad. Sci. U. S. A. 99, 15655-15660 https://doi.org/10.1073/pnas.232137699
  34. Glebe, D. and Urban, S.(2007) Viral and cellular determinants involved in hepadnaviral entry. World J. Gastroenterol. 13, 22-38 https://doi.org/10.3748/wjg.v13.i1.22
  35. Neurath, A. R., Strick, N. and Sproul, P. (1992) Search for hepatitis B virus cell receptors reveals binding sites for interleukin 6 on the virus envelope protein. J. Exp. Med. 175, 461-469 https://doi.org/10.1084/jem.175.2.461
  36. Ryu, C. J., Cho, D. Y., Gripon, P., Kim, H. S., Guguen- Guillouzo, C. and Hong, H. J. (2000) An 80-kilodalton protein that binds to the pre-S1 domain of hepatitis B virus. J. Virol. 74, 110-116 https://doi.org/10.1128/JVI.74.1.110-116.2000
  37. De Falco, S., Ruvoletto, M. G., Verdoliva, A., Ruvo, M., Raucci, A., Marino, M., Senatore, S., Cassani, G., Alberti, A., Pontisso, P. and Fassina, G. (2001) Cloning and expression of a novel hepatitis B virus-binding protein from HepG2 cells. J. Biol. Chem. 276, 36613-36623 https://doi.org/10.1074/jbc.M102377200

Cited by

  1. Backbone resonance assignment of a proteolysis-resistant fragment in the oxygen-dependent degradation domain of the hypoxia inducible factor 1α vol.27, pp.4, 2009, https://doi.org/10.1007/s10059-009-0065-4
  2. Blocking peptides against HBV: PreS1 protein selected from a phage display library vol.412, pp.4, 2011, https://doi.org/10.1016/j.bbrc.2011.08.014
  3. Structural characterization of an intrinsically unfolded mini-HBX protein from hepatitis B virus vol.34, pp.2, 2012, https://doi.org/10.1007/s10059-012-0060-z
  4. Inhibition of Enterovirus 71 (EV-71) Infections by a Novel Antiviral Peptide Derived from EV-71 Capsid Protein VP1 vol.7, pp.5, 2012, https://doi.org/10.1371/journal.pone.0034589
  5. Selection of HBV preS1-binding penta-peptides by phage display vol.46, pp.8, 2014, https://doi.org/10.1093/abbs/gmu049
  6. Hepatitis B virus infection: An insight into infection outcomes and recent treatment options vol.26, pp.1-2, 2015, https://doi.org/10.1007/s13337-015-0247-y
  7. A pre-structured helix in the intrinsically disordered 4EBP1 vol.11, pp.2, 2015, https://doi.org/10.1039/C4MB00532E
  8. Applications of human hepatitis B virus preS domain in bio- and nanotechnology vol.21, pp.24, 2015, https://doi.org/10.3748/wjg.v21.i24.7400
  9. The Mechanism of p53 Rescue by SUSP4 vol.56, pp.5, 2017, https://doi.org/10.1002/anie.201607819
  10. Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure vol.64, pp.8, 2015, https://doi.org/10.1136/gutjnl-2014-308943
  11. Multiple hTAFII31-binding motifs in the intrinsically unfolded transcriptional activation domain of VP16 vol.42, pp.7, 2009, https://doi.org/10.5483/BMBRep.2009.42.7.411
  12. The Mechanism of p53 Rescue by SUSP4 vol.129, pp.5, 2017, https://doi.org/10.1002/ange.201607819
  13. Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications vol.64, pp.1, 2016, https://doi.org/10.1016/j.jhep.2016.02.011
  14. Expression of the PreS1 Peptide of Hepatitis B Virus and Preparation of Its Polyclonal Antibody vol.30, pp.6, 2011, https://doi.org/10.1089/hyb.2011.0065